Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02475213
Recruitment Status : Active, not recruiting
First Posted : June 18, 2015
Last Update Posted : April 14, 2021
Sponsor:
Information provided by (Responsible Party):
MacroGenics

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : October 2021
Estimated Study Completion Date : October 2022